Android app on Google Play

UPDATE: Ariad Pharma (ARIA) Iclusig Launch Not Without Risks; Minority of Physicians View Warnings as Prohibitive

January 3, 2013 11:18 AM EST Send to a Friend
Get Alerts ARIA Hot Sheet
Price: $5.91 --0%

Rating Summary:
    10 Buy, 12 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 9 | Down: 8 | New: 41
Trade ARIA Now!
Join SI Premium – FREE
(Updated - January 3, 2013 11:18 AM EST)

A US survey on ARIAD Pharmaceuticals' (NASDAQ: ARIA) Iclusig suggests some risk to launch, said Oppenheimer. Following the drug's approval by the FDA, which included a box warning arterial thrombosis and liver toxicity, analyst conducted a physician survey.

"The results do not diminish our confidence in Iclusig's significant long-term market opportunity. However, the survey revealed some increased physician caution around Iclusig's side effects and initial adoption,” said analyst David Ferreiro, Ph.D.

"The large majority of surveyed physicians maintained a strong view of Iclusig's profile, despite Iclusig's boxed warning. However, there appears to have emerged a 15% minority of physicians who find Iclusig's arterial thrombosis and liver toxicity to be prohibitive,” said Ferreiro.

Oppenheimer has a Perform rating on ARIAD Pharmaceuticals with a price target of $23.00.

For an analyst ratings summary and ratings history on ARIAD Pharmaceuticals (NASDAQ: ARIA) click here. For more ratings news on ARIAD Pharmaceuticals click here.

Shares of ARIAD Pharmaceuticals closed at $20.09 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS View

Add Your Comment